Dialysis Ultra Filters Articles & Analysis
8 news found
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest. Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access ...
£5.3 million financing to complete First-in-Man safety study Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of ...
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is ...
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts ...
Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round. The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering ...
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have ...